Leerink Swann Starts Nabi Biopharmaceuticals (NABI) at Outperform; NicVAX a Potential Blockbuster Rising from the Ashes
Tweet
Share
E-mailGet Alerts NABI Hot Sheet
Price: $1.80 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Leerink Swann initiates coverage on Nabi Biopharmaceuticals (NASDAQ: NABI) with an Outperform. PT $12.
Leerink analyst says, "NABI is a late development stage biotech company that has divested multiple assets since its inception in 1995. This now lean company is focusing exclusively on lead product NicVAX, a vaccine in development as an aid to smoking cessation and prevention of smoking relapse, currently in Phase III clinical trials with data expected in 2H11 and 1H12."
For more ratings news on Nabi Biopharmaceuticals click here and for the rating history of Nabi Biopharmaceuticals click here.
Shares of Nabi Biopharmaceuticals closed at $5.12 yesterday.
Leerink analyst says, "NABI is a late development stage biotech company that has divested multiple assets since its inception in 1995. This now lean company is focusing exclusively on lead product NicVAX, a vaccine in development as an aid to smoking cessation and prevention of smoking relapse, currently in Phase III clinical trials with data expected in 2H11 and 1H12."
For more ratings news on Nabi Biopharmaceuticals click here and for the rating history of Nabi Biopharmaceuticals click here.
Shares of Nabi Biopharmaceuticals closed at $5.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
- Piper Sandler Starts LightPath Technologies (LPTH) at Overweight
- Fubon Assumes Hon Hai Precision Industry Co Ltd. (2317:TT) (HNHPD) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
